Your browser doesn't support javascript.
loading
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi, Ryan H; Choo, Edna F; Ma, Shuguang; Wong, Susan; Halladay, Jason; Deng, Yuzhong; Rooney, Isabelle; Gates, Mary; Hop, Cornelis E C A; Khojasteh, S Cyrus; Dresser, Mark J; Musib, Luna.
Afiliação
  • Takahashi RH; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California takahashi.ryan@gene.com.
  • Choo EF; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Ma S; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Wong S; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Halladay J; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Deng Y; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Rooney I; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Gates M; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Hop CE; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Khojasteh SC; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Dresser MJ; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
  • Musib L; Departments of Drug Metabolism and Pharmacokinetics (R.H.T., E.F.C., S.M., S.W., J.H., Y.D., C.E.C.A.H., S.C.K.,), Product Development Oncology (I.R.), Early Clinical Development (M.G.), and Clinical Pharmacology (M.J.D, L.M.), Genentech, South San Francisco, California.
Drug Metab Dispos ; 44(1): 28-39, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26451002
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Azetidinas / Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Eliminação Renal / Absorção Intestinal / Mucosa Intestinal / Antineoplásicos Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Azetidinas / Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Eliminação Renal / Absorção Intestinal / Mucosa Intestinal / Antineoplásicos Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article